Development of mRNA manufacturing for vaccines and therapeutics: mRNA platform requirements and development of a scalable production process to support early phase clinical trials

The remarkable success of SARS CoV-2 mRNA-based vaccines and the ensuing interest in mRNA vaccines and therapeutics have highlighted the need for a scalable clinical-enabling manufacturing process to produce such products, and robust analytical methods to demonstrate safety, potency, and purity. To...

Descripción completa

Detalles Bibliográficos
Autores principales: Whitley, Jill, Zwolinski, Christopher, Denis, Christian, Maughan, Maureen, Hayles, Leonie, Clarke, David, Snare, Meghan, Liao, Hong, Chiou, Sean, Marmura, Tina, Zoeller, Holly, Hudson, Ben, Peart, John, Johnson, Monica, Karlsson, Amelia, Wang, Yunfei, Nagle, Cynthia, Harris, Cherell, Tonkin, Daniel, Fraser, Stephanie, Capiz, Lieza, Zeno, Christina L., Meli, Yvonne, Martik, Diana, Ozaki, Daniel A., Caparoni, Amy, Dickens, Jason E., Weissman, Drew, Saunders, Kevin O., Haynes, Barton F., Sempowski, Gregory D., Denny, Thomas N., Johnson, Matthew R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Published by Elsevier Inc. 2022
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8641981/
https://www.ncbi.nlm.nih.gov/pubmed/34871810
http://dx.doi.org/10.1016/j.trsl.2021.11.009

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8641981/
https://www.ncbi.nlm.nih.gov/pubmed/34871810
http://dx.doi.org/10.1016/j.trsl.2021.11.009

Ejemplares similares